apyrase has been researched along with Multiple-Sclerosis--Relapsing-Remitting* in 7 studies
7 other study(ies) available for apyrase and Multiple-Sclerosis--Relapsing-Remitting
Article | Year |
---|---|
Peripheral CD39-expressing T regulatory cells are increased and associated with relapsing-remitting multiple sclerosis in relapsing patients.
CD39, an ectonucleotidase that hydrolyses pro-inflammatory ATP, is a marker of highly active and suppressive T regulatory cells (Tregs). Although CD39 has a role in Treg suppression and might be important in the control of neuroinflammation in relapsing-remitting multiple sclerosis (RR-MS), to date, there are contradictory reports concerning the Tregs expression of CD39 in RR-MS patients. Thus, our objectives were to assess the activity and expression of CD39, especially in Tregs from peripheral blood mononuclear cells (PBMCs) of relapsing RR-MS patients compared with control subjects and to evaluate the association of CD39+ Tregs with disability and the odds of RR-MS. The activity and expression of CD39 and the CD39 Topics: Adenosine Triphosphatases; Adult; Antigens, CD; Apyrase; Cells, Cultured; Female; Fingolimod Hydrochloride; Flow Cytometry; Glatiramer Acetate; Humans; Leukocytes, Mononuclear; Male; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Peripheral Blood Stem Cells; T-Lymphocytes, Regulatory | 2019 |
Regulation of Treg-associated CD39 in multiple sclerosis and effects of corticotherapy during relapse.
Accumulating data highlight proinflammatory processes leading to MS relapses. Whether anti-inflammatory mechanisms are concomitantly activated is unclear. The ectonucleotidase CD39 has been described as a novel T regulatory cell (Treg) marker. The purpose of this study was to explore whether regulatory mechanisms are activated during MS relapses and reinforced by intravenous methylprednisolone (ivMP).. Blood samples were collected from stable and relapsing MS patients and healthy controls. We used FOXP3 methylation-specific qPCR and CD4(+)CD25(high)FOXP3(+) analysis to quantify Tregs. Cytokine mRNA expression levels were measured in peripheral blood mononuclear cells (PBMCs) and in CD4(+) T cells. CD39 expression was determined by flow cytometry in monocytes, NK, T and B cells. CD39 enzymatic activity was assessed by ATP luminometry.. The proportion of Tregs was similar in relapsing MS patients and healthy controls. CD39 mRNA level was higher in PBMCs of relapsing MS patients than in controls. The proportion of CD39-expressing Tregs was higher in MS patients. IvMP decreased the overall proportion of Tregs while it increased CD39 mRNA levels, the proportions of CD39-expressing Tregs and monocytes as well as CD39 ectonucleotidase activity.. Our data suggest that immunoregulatory mechanisms are ongoing in MS patients, particularly during relapses, and strengthened by ivMP. Topics: Administration, Intravenous; Adult; Antigens, CD; Apyrase; Glucocorticoids; Humans; Methylprednisolone; Multiple Sclerosis, Relapsing-Remitting; T-Lymphocytes, Regulatory; Treatment Outcome | 2015 |
Monocytes P2X7 purinergic receptor is modulated by glatiramer acetate in multiple sclerosis.
The aim of this study is to investigate the expression of P2X7R, IL-1beta and the ATP activity modulating ecto-apyrase CD39 on peripheral blood monocytes of MS patients and to observe the possible effects of Glatiramer Acetate (GA) on such expression. Twelve RR treatment-free MS patients were selected and peripheral blood monocytes were obtained. The expression of P2X7R, IL-1beta and CD39 on monocytes was investigated by qrt-PCR. The in vitro effects of GA on the expression of monocytes stimulated with BzATP (a potent P2X7R agonist)-were evaluated. Ten healthy donors (HDs) were similarly studied. Finally, 5 MS patients were given GA therapy and the monocytes obtained before treatment, after 3 and 12 months of GA treatment were similarly investigated. No differences were found in P2X7R, IL-1beta and CD39 expression between patients and controls. In MS Bz-ATP stimulated monocytes, GA pre-conditioning clearly downregulated P2X7R (p=0.003) but IL-1beta expression also showed a decreasing trend (p=0.07). Conversely, CD39 showed an increasing trend (p=0.07). Similar evidence was found in HDs. GA in vivo treatment induced a reduction in the expression that was clear for P2X7R and CD39 (p<0.05) but only not significant for IL-1beta after 12 months of treatment. Monocytes from both MS and control subjects express P2X7R, IL-1beta and CD39, and GA seems to interfere with such expression. Topics: Adult; Antigens, CD; Apyrase; Female; Glatiramer Acetate; Humans; Interleukin-1beta; Male; Middle Aged; Monocytes; Multiple Sclerosis, Relapsing-Remitting; Peptides; Primary Cell Culture; Purinergic P2X Receptor Antagonists; Receptors, Purinergic P2X7 | 2012 |
Th17 expansion in MS patients is counterbalanced by an expanded CD39+ regulatory T cell population during remission but not during relapse.
In this study, percentages of CD39(+) Treg and Th17 cells were compared between relapsing-remitting MS patients and controls and were related to the vitamin D status. The Th17 cell population was expanded in about 40% of the MS patients. In MS patients in remission, but not during relapse, a positive association was found between Th17 cell and CD39(+) Treg percentages (r=0.468, p=0.007). Since CD39(+) Tregs have been shown to have Th17 suppressive capacities, we propose that a dysregulated Th17/CD39(+) Treg balance might contribute to disease exacerbation. A clear role for vitamin D in this regulation could not be established. Topics: Adult; Antigens, CD; Apyrase; Cell Differentiation; Female; Humans; Interleukin-17; Lymphocyte Activation; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; T-Lymphocytes, Regulatory; Th17 Cells; Vitamin D | 2011 |
Activities of the enzymes that hydrolyze adenine nucleotides in platelets from multiple sclerosis patients.
Multiple sclerosis (MS) is the most common chronic disabling neurological disease in young adults. Alterations in platelet function have been observed in MS; however, the mechanism and the relevance of this blood cell disorder with regard to MS pathogenesis are not yet understood. The aim of this study was to evaluate activities of ectonucleoside thiphosphate diphosphohydrolase (NTPDase, CD39), ectonucleotide pyrophosphatase/phosphodiesterase (E-NPP), 5'-nucleotidase and adenosine deaminase (ADA) in platelets from patients with the relapsing-remitting form of MS (RRMS), as well as to analyze platelet aggregation and expression of NTPDase. The results obtained show that NTPDase, 5'-nucleotidase, E-NPP and ADA activities were decreased in platelets of RRMS patients when compared with the control group (p < 0.05). In addition, NTPDase expression in platelets was also decreased in these patients (p < 0.05); however, no differences were observed in platelet aggregation between RRMS patients and the control group. Our results suggest that the alterations in NTPDase, E-NPP, 5'-nucleotidase and ADA may have contributed to the alterations in platelet function in MS by altering the levels of nucleotides and nucleosides in the circulation. Topics: Adenine Nucleotides; Adenosine Deaminase; Adenosine Diphosphate; Adenosine Triphosphate; Adult; Antigens, CD; Apyrase; Blood Platelets; Female; Flow Cytometry; Humans; Hydrolysis; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Nucleotidases; Phosphoric Diester Hydrolases; Platelet Aggregation | 2010 |
Hydrolysis of extracellular ATP and immune suppression: humans versus mice.
Topics: Adenosine Triphosphate; Adult; Animals; Antigens, CD; Apyrase; Dendritic Cells; Female; Forkhead Transcription Factors; Humans; Hydrolysis; Immunosuppression Therapy; Male; Mice; Multiple Sclerosis, Relapsing-Remitting; T-Lymphocytes, Regulatory | 2008 |
Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune suppression.
In the immune system, extracellular ATP functions as a "natural adjuvant" that exhibits multiple proinflammatory effects. It is released by damaged cells as an indicator of trauma and cell death but can be inactivated by CD39 (nucleoside triphosphate diphosphohydrolase-1 [NTPDase 1]), an ectoenzyme that degrades ATP to AMP. Here, we show that CD39 is expressed primarily by immune-suppressive Foxp3(+) regulatory T (Treg) cells. In mice, the enzyme is present on virtually all CD4(+)CD25(+) cells. CD39 expression is driven by the Treg-specific transcription factor Foxp3 and its catalytic activity is strongly enhanced by T-cell receptor (TCR) ligation. Activated Treg cells are therefore able to abrogate ATP-related effects such as P2 receptor-mediated cell toxicity and ATP-driven maturation of dendritic cells. Also, human Treg cells express CD39. In contrast to mice, CD39 expression in man is restricted to a subset of Foxp3(+) regulatory effector/memory-like T (T(REM)) cells. Notably, patients with the remitting/relapsing form of multiple sclerosis (MS) have strikingly reduced numbers of CD39(+) Treg cells in the blood. Thus, in humans CD39 is a marker of a Treg subset likely involved in the control of the inflammatory autoimmune disease. Topics: Adenosine Triphosphate; Adult; Animals; Antigens, CD; Apyrase; Dendritic Cells; Female; Forkhead Transcription Factors; Humans; Hydrolysis; Immunosuppression Therapy; Male; Mice; Multiple Sclerosis, Relapsing-Remitting; T-Lymphocytes, Regulatory | 2007 |